171 related articles for article (PubMed ID: 33563056)
1. Searching for germline mutations in the
Bąk A; Skonieczka K; Jaśkowiec A; Junkiert-Czarnecka A; Heise M; Pilarska-Deltow M; Potoczek S; Czyżewska M; Haus O
Leuk Lymphoma; 2021 Jul; 62(7):1749-1755. PubMed ID: 33563056
[TBL] [Abstract][Full Text] [Related]
2. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
Simon L; Spinella JF; Yao CY; Lavallée VP; Boivin I; Boucher G; Audemard E; Bordeleau ME; Lemieux S; Hébert J; Sauvageau G
Blood; 2020 May; 135(21):1882-1886. PubMed ID: 32315381
[TBL] [Abstract][Full Text] [Related]
3. [A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree].
Guan J; Wang LL; Wang CY; Zhu XM; Shuai HZ; Yi X; Zou L; Yu D; Cheng H
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):393-400. PubMed ID: 37032134
[No Abstract] [Full Text] [Related]
4. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
Migas A; Savva N; Mishkova O; Aleinikova OV
Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
[TBL] [Abstract][Full Text] [Related]
5. In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.
Mendler JH; Maharry K; Becker H; Eisfeld AK; Senter L; Mrózek K; Kohlschmidt J; Metzeler KH; Schwind S; Whitman SP; Khalife J; Caligiuri MA; Klisovic RB; Moore JO; Carter TH; Marcucci G; Bloomfield CD
Haematologica; 2013 Aug; 98(8):e92-4. PubMed ID: 23753029
[No Abstract] [Full Text] [Related]
6. [Familial leukemia due to germline RUNX1 mutations: lessons learned from two decades of research and unsolved problems].
Osato M; Nambu A
Rinsho Ketsueki; 2020; 61(6):687-696. PubMed ID: 32624544
[TBL] [Abstract][Full Text] [Related]
7. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
8. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.
Quesada AE; Montalban-Bravo G; Luthra R; Patel KP; Sasaki K; Bueso-Ramos CE; Khoury JD; Routbort MJ; Bassett R; Hidalgo-Lopez JE; Zhao C; Lin P; Loghavi S; Ok CY; Kadia T; DiNardo CD; Kantarjian H; Garcia-Manero G; Kanagal-Shamanna R
Mod Pathol; 2020 Sep; 33(9):1678-1689. PubMed ID: 32238878
[TBL] [Abstract][Full Text] [Related]
9. RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.
Hyde RK; Liu P; Friedman AD
Adv Exp Med Biol; 2017; 962():265-282. PubMed ID: 28299663
[TBL] [Abstract][Full Text] [Related]
10. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
[TBL] [Abstract][Full Text] [Related]
11. RUNX1 germline variants in RUNX1-mutant AML: how frequent?
Ernst MPT; Kavelaars FG; Löwenberg B; Valk PJM; Raaijmakers MHGP
Blood; 2021 Mar; 137(10):1428-1431. PubMed ID: 33075818
[No Abstract] [Full Text] [Related]
12. Unrelated hematopoietic stem cell transplantation for familial platelet disorder/acute myeloid leukemia with germline RUNX1 mutations.
Toratani K; Watanabe M; Kanda J; Oka T; Hyuga M; Arai Y; Iwasaki M; Sakurada M; Nannya Y; Ogawa S; Yamada T; Takaori-Kondo A
Int J Hematol; 2023 Sep; 118(3):400-405. PubMed ID: 36897502
[TBL] [Abstract][Full Text] [Related]
13. An Old Dog Has a New Trick: Somatic Exonic Deletions in RUNX1 Are Frequent in AML.
Chakraborty J; Stengel KR
Clin Cancer Res; 2023 Aug; 29(15):2742-2744. PubMed ID: 37289016
[TBL] [Abstract][Full Text] [Related]
14. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
[TBL] [Abstract][Full Text] [Related]
15. To T or not to B: germline RUNX1 mutation preferences in pediatric ALL predisposition.
Avagyan S; Brown AL
J Clin Invest; 2021 Sep; 131(17):. PubMed ID: 34623329
[TBL] [Abstract][Full Text] [Related]
16. Reply to "rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases". Haematologica 2014;99(2):e20-21.
Mendler JH; Marcucci G; Bloomfield CD
Haematologica; 2014 Feb; 99(2):e22. PubMed ID: 24497566
[No Abstract] [Full Text] [Related]
17. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
18. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.
Tang JL; Hou HA; Chen CY; Liu CY; Chou WC; Tseng MH; Huang CF; Lee FY; Liu MC; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Lin LI; Tien HF
Blood; 2009 Dec; 114(26):5352-61. PubMed ID: 19808697
[TBL] [Abstract][Full Text] [Related]
19. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.
Mill CP; Fiskus W; DiNardo CD; Qian Y; Raina K; Rajapakshe K; Perera D; Coarfa C; Kadia TM; Khoury JD; Saenz DT; Saenz DN; Illendula A; Takahashi K; Kornblau SM; Green MR; Futreal AP; Bushweller JH; Crews CM; Bhalla KN
Blood; 2019 Jul; 134(1):59-73. PubMed ID: 31023702
[TBL] [Abstract][Full Text] [Related]
20. Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications.
Gonzales F; Barthélémy A; Peyrouze P; Fenwarth L; Preudhomme C; Duployez N; Cheok MH
Expert Opin Ther Targets; 2021 Apr; 25(4):299-309. PubMed ID: 33906574
[No Abstract] [Full Text] [Related]
[Next] [New Search]
